vor-i-KON-a-zole

• Invasive aspergillosis.
• Candidemia (in patients without neutropenia) and serious Candida infections in skin, bladder, abdomen, kidney, and wounds.
• Esophageal candidiasis.
• Scedosporiosis and fusariosis in patients intolerant of or refractory to other therapies.

• Inhibits fungal ergosterol synthesis leading to production of abnormal fungal plasma membrane.

• Antifungal activity.

Spectrum:

• Spectrum is notable for activity against:
  • Aspergillus spp.
  • Candida spp.
  • Scedosporium apiospermum
  • Fusarium spp.

Absorption: Well absorbed following oral administration (96%); IV administration results in complete bioavailability.

Distribution: Extensive tissue distribution.

Protein Binding: 58%.

Metabolism/Excretion: Highly metabolized by the hepatic P450 enzymes (CYP2C19, CYP2C9, CYP3A4); <2% excreted unchanged in urine. Much individual variation in metabolism; metabolites are inactive. The CYP2C19 enzyme system exhibits genetic polymorphism; 15–20% of Asian patients and 3–5% of Caucasian and Black patients may be poor metabolizers and may have significantly ↑ voriconazole concentrations and an ↑ risk of adverse effects.

Half-life: Dose-dependent (adults 6–9 hrs); ↑ in hepatic impairment.

Contraindicated in:

• Concurrent use of dihydroergotamine, carbamazepine, efavirenz (400 mg/day), ergotamine, ivabradine, naloxegol, phenobarbital, pimozide, rifabutin, rifampin, ritonavir (400 mg every 12 hr), quinidine, sirolimus, St. John's wort, tolvaptan, and venetoclax
• Tablets contain lactose and should be avoided in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
• Severe hepatic impairment
• OB: Pregnancy (may cause fetal harm).

Use Cautiously in:

• Mild to moderate hepatic impairment (↓ IV and PO maintenance doses)
• Renal impairment (CCr <50 mL/min) (Vehicle in IV formulation can accumulate resulting in toxicity; avoid use of IV unless potential benefit greatly outweighs potential risk, use oral form only)
• Congenital/acquired QT interval prolongation, HF, sinus bradycardia, hypokalemia, hypomagnesemia, or symptomatic arrhythmias
• Concurrent use of drugs that prolong the QTc interval
• Hematologic malignancy (↑ risk of hepatotoxicity)
• Rep: Women of reproductive potential
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Children <2 yr (safety and effectiveness not established); suspension contains benzyl alcohol which may cause potentially fatal "gasping syndrome" in neonates; ↑ risk of photosensitivity reactions in children.

CV: changes in BP, peripheral edema, QT interval prolongation, tachycardia.

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, MELANOMA, SQUAMOUS CELL CARCINOMA, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS, photosensitivity, rash.

EENT: visual disturbances, eye hemorrhage.

Endo: ADRENAL INSUFFICIENCY.

F and E: hypokalemia, hypomagnesemia, hyperglycemia.

GI: HEPATOTOXICITY, abdominal pain, diarrhea, nausea, pancreatitis, vomiting.

MS: fluorosis, periostitis.

Neuro: dizziness, hallucinations, headache.

Misc: chills, fever, infusion reactions.

Drug-Drug:

• Voriconazole is a substrate and inhibitor of the CYP3A4, CYP2C9, and CYP2C19 enzyme systems.
• Carbamazepine, phenobarbital, and rifampin may significantly ↓ levels and effectiveness; concurrent use contraindicated.
• May significantly ↑ levels of ivabradine, pimozide, and quinidine, which can ↑ the risk of QT interval prolongation and torsades de pointes; concurrent use contraindicated.
• May significantly ↑ levels and risk of toxicity of dihydroergotamine, ergotamine, sirolimus, and tolvaptan; concurrent use contraindicated. ,
• May ↑ levels of naloxegol which could precipitate symptoms of opioid withdrawal; concurrent use contraindicated.
• Concurrent use with efavirenz at doses of 400 mg every 24 hr is contraindicated since it may significantly ↑ efavirenz levels and significantly ↓ voriconazole levels; if used together, ↑ oral maintenance dose of voriconazole to 400 mg every 12 hr and ↓ dose of efavirenz to 300 mg daily.
• Concurrent use with ritonavir at dose of 400 mg every 12 hr is contraindicated since ritonavir may significantly ↓ voriconazole levels; use with ritonavir at dose of 100 mg every 12 hr should also be avoided, if possible.
• Concurrent use with rifabutin may significantly ↑ rifabutin levels and significantly ↓ voriconazole levels; if used together, ↑ oral maintenance dose of voriconazole to 400 mg every 12 hr and ↓ dose of efavirenz to 300 mg daily.
• Concurrent use with venetoclax at initiation and during ramp-up phase in patients with chronic lymphocytic leukemia or small lymphocytic leukemia is contraindicated because may ↑ risk of tumor lysis syndrome.
• Fluconazole may ↑ levels of voriconazole; avoid concurrent use.
• May ↑ levels of cyclosporine; ↓ cyclosporine dose by 50%.
• May ↑ levels of tacrolimus; ↓ tacrolimus dose to 1/3 of the starting dose.
• May ↑ levels of HMG-CoA reductase inhibitors, some benzodiazepines (alprazolam, midazolam, triazolam), fentanyl, oxycodone, NSAIDs (ibuprofen, diclofenac), some calcium channel blockers, sulfonylureas (glipizide, glyburide), phenytoin, alfentanil, warfarin, and vinca alkaloids (vincristine, vinblastine); dose ↓ may be needed and careful monitoring required during concurrent use.
• May ↑ methadone levels and ↑ risk of QT interval prolongation.
• May ↑ levels of corticosteroids and ↑ risk of adrenal suppression.
• May ↑ levels and risk of toxicity of ivacaftor; ↓ ivacaftor dose.
• Concurrent use with hormonal contraceptives containing ethinyl estradiol and norethindrone may ↑ voriconazole, ethinyl estradiol and norethindrone levels.
• May ↑ levels of everolimus; concurrent use not recommended.
• ↑blood levels of omeprazole; if patient receiving 40 mg/day of omeprazole, ↓ omeprazole dose by 50%. Similar effects may occur with other proton-pump inhibitors.
• May ↓ metabolism and ↑ blood levels and effects of protease-inhibitor antiretrovirals and non-nucleoside reverse transcriptase inhibitor antiretrovirals; frequent monitoring recommended.
• Non-nucleoside reverse transcriptase inhibitor antiretrovirals; may induce or inhibit the metabolism of voriconazole; frequent monitoring recommended.
• Letermovir may ↓ levels; avoid concurrent use.

Drug-Natural Products:

• St. John's wort may significantly ↓ levels and effectiveness; concurrent use contraindicated.

Invasive Aspergillosis, Scedosporiosis, or Fusariosis

• IV, PO (Adults 40 kg): Loading dose (IV) — 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV)of 4 mg/kg IV every 12 hr (use 5 mg/kg IV every 12 hr if concurrently using with phenytoin). Continue IV therapy for 7 days, then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 200 mg PO every 12 hr (use 400 mg PO every 12 hr if concurrently using with phenytoin or efavirenz); if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: 6–12 wk.
• IV, PO (Adults <40 kg): Loading dose (IV) — 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 4 mg/kg IV every 12 hr (use 5 mg/kg IV every 12 hr if concurrently using with phenytoin). Continue IV therapy for 7 days, then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 100 mg PO every 12 hr (use 200 mg PO every 12 hr if concurrently using with phenytoin; use 400 mg PO every 12 hr if concurrently using with efavirenz); if response inadequate, may ↑ to 150 mg every 12 hr. Total duration of therapy: 6–12 wk.
• IV, PO (Children 15 yr): Loading dose (IV) — 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 4 mg/kg IV every 12 hr. Continue IV therapy for 7 days, then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: 6–12 wk.
• IV, PO (Children 12–14 yr and 50 kg): Loading dose (IV) — 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 4 mg/kg IV every 12 hr. Continue IV therapy for 7 days, then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: 6–12 wk.
• IV, PO (Children 12–14 yr and <50 kg): Loading dose (IV) — 9 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 8 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Continue IV therapy for 7 days, then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: 6–12 wk.
• IV, PO (Children 2–11 yr): Loading dose (IV) — 9 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 8 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Continue IV therapy for 7 days, then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: 6–12 wk.

Candidemia in Non-Neutropenic Patients or Other Deep Tissue Candida Infections

• IV, PO (Adults 40 kg): Loading dose (IV) — 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 3–4 mg/kg IV every 12 hr (use 5 mg/kg IV every 12 hr if concurrently using with phenytoin). Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 200 mg PO every 12 hr (use 400 mg PO every 12 hr if concurrently using with phenytoin or efavirenz); if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: 14 days following resolution of symptoms or following last positive culture, whichever is longer.
• IV, PO (Adults <40 kg): Loading dose (IV) — 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 3–4 mg/kg IV every 12 hr (use 5 mg/kg IV every 12 hr if concurrently using with phenytoin). Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 100 mg PO every 12 hr (use 200 mg PO every 12 hr if concurrently using with phenytoin; use 400 mg PO every 12 hr if using concurrently with efavirenz); if response inadequate, may ↑ to 150 mg every 12 hr. Total duration of therapy: 14 days following resolution of symptoms or following last positive culture, whichever is longer.
• IV, PO (Children 15 yr): Loading dose (IV) — 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 3–4 mg/kg IV every 12 hr. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: 14 days following resolution of symptoms or following last positive culture, whichever is longer.
• IV, PO (Children 12–14 yr and 50 kg): Loading dose (IV) — 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 3–4 mg/kg IV every 12 hr. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: 14 days following resolution of symptoms or following last positive culture, whichever is longer.
• IV, PO (Children 12–14 yr and <50 kg): Loading dose (IV) — 9 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 8 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: 14 days following resolution of symptoms or following last positive culture, whichever is longer.
• IV, PO (Children 2–11 yr): Loading dose (IV) — 9 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 8 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: 14 days following resolution of symptoms or following last positive culture, whichever is longer.

Esophageal Candidiasis

• PO (Adults 40 kg): 200 mg every 12 hr (use 400 mg every 12 hr if concurrently using with phenytoin or efavirenz); if response inadequate, may ↑ to 300 mg every 12 hr. Duration of therapy: 14 days and for 7 days following resolution of symptoms.
• PO (Adults <40 kg): 100 mg every 12 hr (use 200 mg every 12 hr if concurrently using with phenytoin; use 400 mg every 12 hr if using concurrently with efavirenz); if response inadequate, may ↑ to 150 mg every 12 hr. Duration of therapy: 14 days and for 7 days following resolution of symptoms.
• PO (Children 15 yr): 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Duration of therapy: 14 days and for 7 days following resolution of symptoms.
• PO (Children 12–14 yr and 50 kg): 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Duration of therapy: 14 days and for 7 days following resolution of symptoms.
• IV, PO (Children 12–14 yr and <50 kg): Initiate therapy with maintenance dose (IV) of 4 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: 14 days and for 7 days following resolution of symptoms.
• IV, PO (Children 2–11 yr): Initiate therapy with maintenance dose (IV) of 4 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO) — 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: 14 days and for 7 days following resolution of symptoms.

• Once patient can tolerate oral medication, PO voriconazole may be used.
• Correct electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia) prior to initiation and during therapy.
• PO: Administer at least 1 hr before or 1 hr after a meal.
  • Shake suspension well (approximately 10 sec) before measuring suspension. Use oral dispenser provided to ensure accurate dose. Do not mix suspension with other medicine, flavored liquid, or syrup. Store suspension at room temperature up to 14 days, then discard.

IV Administration:

• Do not administer voriconazole with blood products or concentrated electrolytes, even in separate lines. Non-concentrated electrolytes can be infused at same time, but separate lines must be used. TPN can be administered simultaneously but must be via separate line or via a different port in a multi-lumen catheter.
• Intermittent Infusion: Reconstitution: Reconstitute each 200-mg vial with 19 mL of sterile water for injection to achieve concentration of 10 mg/mL. Calculate volume of 10 mg/mL solution required for patient dose.
  Diluent: Withdraw and discard equal volume of diluent from infusion bag or bottle to be used. Withdraw required volume of voriconazole solution from vial(s) and add to appropriate volume of 0.9% NaCl, LR, D5/LR, D5/0.45% NaCl, D5W, 0.45% NaCl, or D5/0.9% NaCl. Reconstituted solution stable for 24 hr if refrigerated. Discard partially used vials.Concentration: Final concentration of infusion should be 0.5–5 mg/mL.
• Rate: Infuse over 1–3 hr at a rate not to exceed 3 mg/kg/hr.
• Y-Site Compatibility:
  • acyclovir
  • alemtuzumab
  • alfentanil
  • allopurinol
  • amifostine
  • amikacin
  • aminocaproic acid
  • aminophylline
  • amiodarone
  • amphotericin B liposome
  • ampicillin
  • ampicillin/sulbactam
  • anidulafungin
  • argatroban
  • arsenic trioxide
  • azithromycin
  • aztreonam
  • bivalirudin
  • bleomycin
  • buprenorphine
  • butorphanol
  • bumetanide
  • buprenorphine
  • butorphanol
  • calcium acetate
  • calcium chloride
  • calcium gluconate
  • cangrelor
  • carboplatin
  • carmustine
  • caspofungin
  • cefazolin
  • cefotaxime
  • cefotetan
  • cefoxitin
  • ceftaroline
  • ceftazidime
  • ceftriaxone
  • chloramphenicol
  • chlorpromazine
  • ciprofloxacin
  • cisatracurium
  • cisplatin
  • clindamycin
  • cyclophosphamide
  • cytarabine
  • dacarbazine
  • dactinomycin
  • daptomycin
  • daunorubicin hydrochloride
  • dexamethasone
  • dexmedetomidine
  • dexrazoxane
  • digoxin
  • diltiazem
  • diphenhydramine
  • dobutamine
  • docetaxel
  • dopamine
  • doxycycline
  • droperidol
  • enalaprilat
  • ephedrine
  • epinephrine
  • epirubicin
  • ertapenem
  • erythromycin
  • esmolol
  • etoposide
  • etoposide phosphate
  • famotidine
  • fenoldopam
  • fentanyl
  • fluconazole
  • fludarabine
  • fluorouracil
  • foscarnet
  • fosphenytoin
  • furosemide
  • ganciclovir
  • gemcitabine
  • gentamicin
  • glycopyrrolate
  • granisetron
  • haloperidol
  • heparin
  • hydralazine
  • hydrocortisone
  • ifosfamide
  • imipenem/cilastatin
  • insulin, regular
  • irinotecan
  • isoproterenol
  • ketorolac
  • labetalol
  • leucovorin calcium
  • levofloxacin
  • lidocaine
  • linezolid
  • lorazepam
  • magnesium sulfate
  • mannitol
  • melphalan
  • meperidine
  • meropenem
  • mesna
  • methadone
  • methohexital
  • methotrexate
  • methylprednisolone
  • metoclopramide
  • metoprolol
  • metronidazole
  • midazolam
  • milrinone
  • mitomycin
  • morphine
  • mycophenolate
  • nafcillin
  • nalbuphine
  • naloxone
  • nicardipine
  • nitroglycerin
  • norepinephrine
  • octreotide
  • ondansetron
  • oxaliplatin
  • oxytocin
  • paclitaxel
  • pamidronate
  • pancuronium
  • pentamidine
  • pentobarbital
  • phenobarbital
  • phenylephrine
  • piperacillin/tazobactam
  • potassium acetate
  • potassium chloride
  • potassium phosphate
  • procainamide
  • promethazine
  • propranolol
  • quinupristin/dalfopristin
  • remifentanil
  • rocuronium
  • sodium acetate
  • sodium bicarbonate
  • sodium phosphate
  • streptozocin
  • succinylcholine
  • sufentanil
  • tacrolimus
  • theophylline
  • thiotepa
  • tirofiban
  • tobramycin
  • topotecan
  • trimethoprim/sulfamethoxazole
  • vancomycin
  • vasopressin
  • vecuronium
  • verapamil
  • vinblastine
  • vincristine
  • vinorelbine
  • zidovudine
  • zoledronic acid
• Y-Site Incompatibility:
  • amphotericin B deoxycholate
  • amphotericin B lipid complex
  • busulfan
  • cefepime
  • cyclosporine
  • dantrolene
  • diazepam
  • doxorubicin hydrochloride
  • gemtuzumab ozogamicin
  • idarubicin
  • mitoxantrone
  • moxifloxacin
  • nitroprusside
  • pantoprazole
  • phenytoin
  • thiopental
.

Vfend

Therapeutic Classification: antifungals

(Generic available)

• Tablets: 50 mg; 200 mg;
• Oral suspension (orange-flavor): 40 mg/mL;
• Powder for injection: 200 mg/vial;

(blood levels)

• Monitor for signs and symptoms of fungal infections prior to and during therapy.
• Obtain specimens for culture and histopathology prior to therapy to isolate and identify organism. Therapy may be started before results are received.
• Monitor visual function including visual acuity, visual field, and color perception in patients receiving more than 28 days of therapy. Vision usually returns to normal within 14 days after discontinuation of therapy.
• Monitor for allergic reactions during infusion of voriconazole (flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faintness, nausea, pruritus, rash). Symptoms occur immediately upon start of infusion. May require discontinuation.
• Monitor patients with risk factors for acute pancreatitis (recent chemotherapy, hematopoietic stem cell transplantation [HSCT]) for the signs of pancreatitis (abdominal pain, ↑ serum amylase and lipase).
• Assess for rash periodically during therapy. May cause SJS. Discontinue therapy if severe or if accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia.

• Monitor liver function tests (AST, ALT, and bilirubin) prior to, weekly during first mo and monthly during therapy. If abnormal liver function tests occur, monitor for development of severe hepatic injury. Discontinue therapy if markedly ↑ or clinical signs and symptoms of liver disease develop.
  • Monitor renal function (serum creatinine) during therapy.

• Advise patient to take voriconazole as directed, on an empty stomach. Advise patient to read Patient Information before starting voriconazole and with each Rx refill in case of changes.
• May cause blurred vision, photophobia, and dizziness. Caution patient to avoid driving and other activities requiring alertness until response to medication is known. Also advise patient to avoid driving at night during voriconazole therapy.
• Advise patient to avoid direct sunlight, sunlamps and tanning beds during voriconazole therapy. Use sunscreen and protective clothing to prevent severe sunburn. Advise patient to have dermatologic evaluation regular basis to allow early detection and management of premalignant lesions; squamous cell carcinoma of the skin and melanoma have been reported during long-term therapy.
• Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
• Advise patient to notify health care professional if rash or signs and symptoms of allergic reaction occur.
• Rep: May cause fetal harm. Advise females of reproductive potential to use effective contraception and notify health care professional if pregnancy is planned or suspected, or if breast feeding. Monitor for adverse reactions if voriconazole is administered concurrently with oral contraceptives. If pregnancy is detected, discontinue medication as soon as possible.

• Resolution of fungal infections.

NDC Code^*

• 0049- Roerig
  • 0049-3160- VFEND
    • 0049-3160-44- 1 BOTTLE in 1 CARTON (0049-3160-44) > 75 mL in 1 BOTTLE

• 0049- Roerig
  • 0049-3170- VFEND
    • 0049-3170-30- 30 TABLET, FILM COATED in 1 BOTTLE (0049-3170-30)

• 0049- Roerig
  • 0049-3180- VFEND
    • 0049-3180-30- 30 TABLET, FILM COATED in 1 BOTTLE (0049-3180-30)

• 0049- Roerig
  • 0049-3190- VFEND
    • 0049-3190-38- 20 mL in 1 VIAL, SINGLE-USE (0049-3190-38)

• 0049- Roerig
  • 0049-3190- VFEND
    • 0049-3190-28- 1 VIAL, SINGLE-DOSE in 1 CARTON (0049-3190-28) > 20 mL in 1 VIAL, SINGLE-DOSE

• 0049- Roerig
  • 0049-3190- VFEND
    • 0049-3190-01- 1 VIAL, SINGLE-USE in 1 CARTON (0049-3190-01) > 20 mL in 1 VIAL, SINGLE-USE

• 0049- Roerig
  • 0049-4190- VFEND
    • 0049-4190-01- 1 VIAL, SINGLE-USE in 1 CARTON (0049-4190-01) > 20 mL in 1 VIAL, SINGLE-USE

• 0378- Mylan Pharmaceuticals Inc.
  • 0378-1626- Voriconazole
    • 0378-1626-93- 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-1626-93)

• 0378- Mylan Pharmaceuticals Inc.
  • 0378-1640- Voriconazole
    • 0378-1640-93- 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-1640-93)

• 0781- Sandoz Inc
  • 0781-3416- Voriconazole
    • 0781-3416-94- 1 VIAL, SINGLE-USE in 1 CARTON (0781-3416-94) > 20 mL in 1 VIAL, SINGLE-USE

• 0781- Sandoz Inc
  • 0781-5667- voriconazole
    • 0781-5667-05- 500 TABLET, FILM COATED in 1 BOTTLE (0781-5667-05)

• 0781- Sandoz Inc
  • 0781-5667- voriconazole
    • 0781-5667-10- 1000 TABLET, FILM COATED in 1 BOTTLE (0781-5667-10)

• 0781- Sandoz Inc
  • 0781-5667- voriconazole
    • 0781-5667-13- 10 BLISTER PACK in 1 CARTON (0781-5667-13) > 10 TABLET, FILM COATED in 1 BLISTER PACK (0781-5667-06)

• 0781- Sandoz Inc
  • 0781-5667- voriconazole
    • 0781-5667-31- 30 TABLET, FILM COATED in 1 BOTTLE (0781-5667-31)

• 0781- Sandoz Inc
  • 0781-5668- voriconazole
    • 0781-5668-05- 500 TABLET, FILM COATED in 1 BOTTLE (0781-5668-05)

• 0781- Sandoz Inc
  • 0781-5668- voriconazole
    • 0781-5668-10- 1000 TABLET, FILM COATED in 1 BOTTLE (0781-5668-10)

• 0781- Sandoz Inc
  • 0781-5668- voriconazole
    • 0781-5668-13- 10 BLISTER PACK in 1 CARTON (0781-5668-13) > 10 TABLET, FILM COATED in 1 BLISTER PACK (0781-5668-06)

• 0781- Sandoz Inc
  • 0781-5668- voriconazole
    • 0781-5668-31- 30 TABLET, FILM COATED in 1 BOTTLE (0781-5668-31)

• 0904- Major Pharmaceuticals
  • 0904-6471- voriconazole
    • 0904-6471-04- 30 TABLET, FILM COATED in 1 BOX, UNIT-DOSE (0904-6471-04)

• 0904- Major Pharmaceuticals
  • 0904-6596- voriconazole
    • 0904-6596-04- 30 BLISTER PACK in 1 CARTON (0904-6596-04) > 1 TABLET in 1 BLISTER PACK

• 14335- Hainan Poly Pharm. Co., Ltd.
  • 14335-080- Voriconazole
    • 14335-080-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (14335-080-01) > 20 mL in 1 VIAL, SINGLE-DOSE

• 16714- Northstar Rx LLC
  • 16714-514- Voriconazole
    • 16714-514-01- 30 TABLET in 1 BOTTLE (16714-514-01)

• 16714- Northstar Rx LLC
  • 16714-515- Voriconazole
    • 16714-515-01- 30 TABLET in 1 BOTTLE (16714-515-01)

• 27241- Ajanta Pharma Limited
  • 27241-062- Voriconazole
    • 27241-062-03- 30 TABLET in 1 BOTTLE (27241-062-03)

• 27241- Ajanta Pharma Limited
  • 27241-063- Voriconazole
    • 27241-063-03- 30 TABLET in 1 BOTTLE (27241-063-03)

• 39822- X-Gen Pharmaceuticals Inc
  • 39822-1077- Voriconazole
    • 39822-1077-1- 1 VIAL, SINGLE-USE in 1 CARTON (39822-1077-1) > 20 mL in 1 VIAL, SINGLE-USE

• 40032- Novel Laboratories, Inc.
  • 40032-038- voriconazole
    • 40032-038-60- 1 BOTTLE in 1 CARTON (40032-038-60) > 75 mL in 1 BOTTLE

• 43386- Lupin Pharmaceuticals,Inc.
  • 43386-038- VORICONAZOLE
    • 43386-038-60- 1 BOTTLE in 1 CARTON (43386-038-60) > 75 mL in 1 BOTTLE (43386-038-00)

• 43386- Lupin Pharmaceuticals,Inc.
  • 43386-088- voriconazole
    • 43386-088-03- 30 TABLET, FILM COATED in 1 BOTTLE (43386-088-03)

• 43386- Lupin Pharmaceuticals,Inc.
  • 43386-088- voriconazole
    • 43386-088-05- 500 TABLET, FILM COATED in 1 BOTTLE (43386-088-05)

• 43386- Lupin Pharmaceuticals,Inc.
  • 43386-088- voriconazole
    • 43386-088-31- 3 BLISTER PACK in 1 CARTON (43386-088-31) > 10 TABLET, FILM COATED in 1 BLISTER PACK (43386-088-30)

• 43386- Lupin Pharmaceuticals,Inc.
  • 43386-089- voriconazole
    • 43386-089-03- 30 TABLET, FILM COATED in 1 BOTTLE (43386-089-03)

• 43386- Lupin Pharmaceuticals,Inc.
  • 43386-089- voriconazole
    • 43386-089-05- 500 TABLET, FILM COATED in 1 BOTTLE (43386-089-05)

• 43386- Lupin Pharmaceuticals,Inc.
  • 43386-089- voriconazole
    • 43386-089-31- 3 BLISTER PACK in 1 CARTON (43386-089-31) > 10 TABLET, FILM COATED in 1 BLISTER PACK (43386-089-30)

• 43547- Solco Healthcare U.S., LLC
  • 43547-377- Voriconazole
    • 43547-377-03- 30 TABLET, COATED in 1 BOTTLE (43547-377-03)

• 43547- Solco Healthcare U.S., LLC
  • 43547-377- Voriconazole
    • 43547-377-50- 500 TABLET, COATED in 1 BOTTLE (43547-377-50)

• 43547- Solco Healthcare U.S., LLC
  • 43547-378- Voriconazole
    • 43547-378-03- 30 TABLET, COATED in 1 BOTTLE (43547-378-03)

• 43547- Solco Healthcare U.S., LLC
  • 43547-378- Voriconazole
    • 43547-378-50- 500 TABLET, COATED in 1 BOTTLE (43547-378-50)

• 47781- Alvogen Inc.
  • 47781-466- VORICONAZOLE
    • 47781-466-71- 1 VIAL in 1 CARTON (47781-466-71) > 20 mL in 1 VIAL

• 51079- Mylan Institutional Inc.
  • 51079-164- Voriconazole
    • 51079-164-03- 30 BLISTER PACK in 1 CARTON (51079-164-03) > 1 TABLET, FILM COATED in 1 BLISTER PACK (51079-164-01)

• 51079- Mylan Institutional Inc.
  • 51079-165- Voriconazole
    • 51079-165-03- 30 BLISTER PACK in 1 CARTON (51079-165-03) > 1 TABLET, FILM COATED in 1 BLISTER PACK (51079-165-01)

• 51407- Golden State Medical Supply Inc.
  • 51407-133- voriconazole
    • 51407-133-30- 30 TABLET, FILM COATED in 1 BOTTLE (51407-133-30)

• 59762- Greenstone LLC
  • 59762-0930- Voriconazole
    • 59762-0930-2- 30 TABLET, FILM COATED in 1 BOTTLE (59762-0930-2)

• 59762- Greenstone LLC
  • 59762-0934- Voriconazole
    • 59762-0934-1- 30 TABLET, FILM COATED in 1 BOTTLE (59762-0934-1)

• 59762- Greenstone LLC
  • 59762-0935- Voriconazole
    • 59762-0935-3- 1 BOTTLE in 1 CARTON (59762-0935-3) > 75 mL in 1 BOTTLE

• 59762- Greenstone LLC
  • 59762-0936- Voriconazole
    • 59762-0936-1- 30 TABLET, FILM COATED in 1 BOTTLE (59762-0936-1)

• 60429- Golden State Medical Supply, Inc.
  • 60429-915- voriconazole
    • 60429-915-30- 30 TABLET, FILM COATED in 1 BOTTLE (60429-915-30)

• 60429- Golden State Medical Supply, Inc.
  • 60429-916- voriconazole
    • 60429-916-30- 30 TABLET, FILM COATED in 1 BOTTLE (60429-916-30)

• 60687- American Health Packaging
  • 60687-273- Voriconazole
    • 60687-273-21- 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-273-21) > 1 TABLET, FILM COATED in 1 BLISTER PACK (60687-273-11)

• 60687- American Health Packaging
  • 60687-294- Voriconazole
    • 60687-294-21- 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-294-21) > 1 TABLET, FILM COATED in 1 BLISTER PACK (60687-294-11)

• 61748- VersaPharm Incorporated
  • 61748-365- Voriconazole
    • 61748-365-30- 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61748-365-30)

• 61748- VersaPharm Incorporated
  • 61748-366- Voriconazole
    • 61748-366-30- 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61748-366-30)

• 63739- McKesson Corporation dba SKY Packaging
  • 63739-707- voriconazole
    • 63739-707-33- 3 BLISTER PACK in 1 BOX, UNIT-DOSE (63739-707-33) > 10 TABLET, FILM COATED in 1 BLISTER PACK

• 64980- Rising Pharmaceuticals, Inc.
  • 64980-274- voriconazole
    • 64980-274-03- 30 TABLET, FILM COATED in 1 BOTTLE (64980-274-03)

• 64980- Rising Pharmaceuticals, Inc.
  • 64980-275- voriconazole
    • 64980-275-03- 30 TABLET, FILM COATED in 1 BOTTLE (64980-275-03)

• 65162- Amneal Pharmaceuticals LLC
  • 65162-913- Voriconazole
    • 65162-913-22- 75 mL in 1 BOTTLE (65162-913-22)

• 65841- Cadila Healthcare Limited
  • 65841-830- voriconazole
    • 65841-830-01- 100 TABLET in 1 BOTTLE (65841-830-01)

• 65841- Cadila Healthcare Limited
  • 65841-830- voriconazole
    • 65841-830-05- 500 TABLET in 1 BOTTLE (65841-830-05)

• 65841- Cadila Healthcare Limited
  • 65841-830- voriconazole
    • 65841-830-06- 30 TABLET in 1 BOTTLE (65841-830-06)

• 65841- Cadila Healthcare Limited
  • 65841-830- voriconazole
    • 65841-830-10- 1000 TABLET in 1 BOTTLE (65841-830-10)

• 65841- Cadila Healthcare Limited
  • 65841-830- voriconazole
    • 65841-830-16- 90 TABLET in 1 BOTTLE (65841-830-16)

• 65841- Cadila Healthcare Limited
  • 65841-830- voriconazole
    • 65841-830-77- 10 BLISTER PACK in 1 CARTON (65841-830-77) > 10 TABLET in 1 BLISTER PACK (65841-830-30)

• 65841- Cadila Healthcare Limited
  • 65841-831- voriconazole
    • 65841-831-01- 100 TABLET in 1 BOTTLE (65841-831-01)

• 65841- Cadila Healthcare Limited
  • 65841-831- voriconazole
    • 65841-831-05- 500 TABLET in 1 BOTTLE (65841-831-05)

• 65841- Cadila Healthcare Limited
  • 65841-831- voriconazole
    • 65841-831-06- 30 TABLET in 1 BOTTLE (65841-831-06)

• 65841- Cadila Healthcare Limited
  • 65841-831- voriconazole
    • 65841-831-10- 1000 TABLET in 1 BOTTLE (65841-831-10)

• 65841- Cadila Healthcare Limited
  • 65841-831- voriconazole
    • 65841-831-16- 90 TABLET in 1 BOTTLE (65841-831-16)

• 65841- Cadila Healthcare Limited
  • 65841-831- voriconazole
    • 65841-831-77- 10 BLISTER PACK in 1 CARTON (65841-831-77) > 10 TABLET in 1 BLISTER PACK (65841-831-30)

• 65862- Aurobindo Pharma Limited
  • 65862-891- Voriconazole
    • 65862-891-01- 100 TABLET, FILM COATED in 1 BOTTLE (65862-891-01)

• 65862- Aurobindo Pharma Limited
  • 65862-891- Voriconazole
    • 65862-891-03- 3 BLISTER PACK in 1 CARTON (65862-891-03) > 10 TABLET, FILM COATED in 1 BLISTER PACK (65862-891-10)

• 65862- Aurobindo Pharma Limited
  • 65862-891- Voriconazole
    • 65862-891-05- 500 TABLET, FILM COATED in 1 BOTTLE (65862-891-05)

• 65862- Aurobindo Pharma Limited
  • 65862-891- Voriconazole
    • 65862-891-30- 30 TABLET, FILM COATED in 1 BOTTLE (65862-891-30)

• 65862- Aurobindo Pharma Limited
  • 65862-892- Voriconazole
    • 65862-892-01- 100 TABLET, FILM COATED in 1 BOTTLE (65862-892-01)

• 65862- Aurobindo Pharma Limited
  • 65862-892- Voriconazole
    • 65862-892-03- 3 BLISTER PACK in 1 CARTON (65862-892-03) > 10 TABLET, FILM COATED in 1 BLISTER PACK (65862-892-10)

• 65862- Aurobindo Pharma Limited
  • 65862-892- Voriconazole
    • 65862-892-05- 500 TABLET, FILM COATED in 1 BOTTLE (65862-892-05)

• 65862- Aurobindo Pharma Limited
  • 65862-892- Voriconazole
    • 65862-892-30- 30 TABLET, FILM COATED in 1 BOTTLE (65862-892-30)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-735- voriconazole
    • 68382-735-01- 100 TABLET in 1 BOTTLE (68382-735-01)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-735- voriconazole
    • 68382-735-05- 500 TABLET in 1 BOTTLE (68382-735-05)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-735- voriconazole
    • 68382-735-06- 30 TABLET in 1 BOTTLE (68382-735-06)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-735- voriconazole
    • 68382-735-10- 1000 TABLET in 1 BOTTLE (68382-735-10)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-735- voriconazole
    • 68382-735-16- 90 TABLET in 1 BOTTLE (68382-735-16)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-735- voriconazole
    • 68382-735-77- 10 BLISTER PACK in 1 CARTON (68382-735-77) > 10 TABLET in 1 BLISTER PACK (68382-735-30)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-736- voriconazole
    • 68382-736-01- 100 TABLET in 1 BOTTLE (68382-736-01)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-736- voriconazole
    • 68382-736-05- 500 TABLET in 1 BOTTLE (68382-736-05)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-736- voriconazole
    • 68382-736-06- 30 TABLET in 1 BOTTLE (68382-736-06)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-736- voriconazole
    • 68382-736-10- 1000 TABLET in 1 BOTTLE (68382-736-10)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-736- voriconazole
    • 68382-736-16- 90 TABLET in 1 BOTTLE (68382-736-16)

• 68382- Zydus Pharmaceuticals (USA) Inc.
  • 68382-736- voriconazole
    • 68382-736-77- 10 BLISTER PACK in 1 CARTON (68382-736-77) > 10 TABLET in 1 BLISTER PACK (68382-736-30)

• 68462- Glenmark Pharmaceuticals Inc., USA
  • 68462-572- voriconazole
    • 68462-572-13- 3 BLISTER PACK in 1 CARTON (68462-572-13) > 10 TABLET, FILM COATED in 1 BLISTER PACK

• 68462- Glenmark Pharmaceuticals Inc., USA
  • 68462-572- voriconazole
    • 68462-572-30- 30 TABLET, FILM COATED in 1 BOTTLE (68462-572-30)

• 68462- Glenmark Pharmaceuticals Inc., USA
  • 68462-572- voriconazole
    • 68462-572-90- 90 TABLET, FILM COATED in 1 BOTTLE (68462-572-90)

• 68462- Glenmark Pharmaceuticals Inc., USA
  • 68462-573- voriconazole
    • 68462-573-13- 3 BLISTER PACK in 1 CARTON (68462-573-13) > 10 TABLET, FILM COATED in 1 BLISTER PACK

• 68462- Glenmark Pharmaceuticals Inc., USA
  • 68462-573- voriconazole
    • 68462-573-30- 30 TABLET, FILM COATED in 1 BOTTLE (68462-573-30)

• 68462- Glenmark Pharmaceuticals Inc., USA
  • 68462-573- voriconazole
    • 68462-573-90- 90 TABLET, FILM COATED in 1 BOTTLE (68462-573-90)

• 70436- Slate Run Pharmaceuticals
  • 70436-029- voriconazole
    • 70436-029-80- 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 BOX (70436-029-80)

• 70710- Zydus Pharmaceuticals (USA) Inc.
  • 70710-1247- VORICONAZOLE
    • 70710-1247-1- 1 VIAL, SINGLE-DOSE in 1 CARTON (70710-1247-1) > 20 mL in 1 VIAL, SINGLE-DOSE

• 70771- Cadila Healthcare Limited
  • 70771-1413- VORICONAZOLE
    • 70771-1413-1- 1 VIAL, SINGLE-DOSE in 1 CARTON (70771-1413-1) > 20 mL in 1 VIAL, SINGLE-DOSE

• 72578- Viona Pharmaceuticals Inc
  • 72578-062- voriconazole
    • 72578-062-01- 100 TABLET in 1 BOTTLE (72578-062-01)

• 72578- Viona Pharmaceuticals Inc
  • 72578-062- voriconazole
    • 72578-062-05- 500 TABLET in 1 BOTTLE (72578-062-05)

• 72578- Viona Pharmaceuticals Inc
  • 72578-062- voriconazole
    • 72578-062-06- 30 TABLET in 1 BOTTLE (72578-062-06)

• 72578- Viona Pharmaceuticals Inc
  • 72578-062- voriconazole
    • 72578-062-10- 1000 TABLET in 1 BOTTLE (72578-062-10)

• 72578- Viona Pharmaceuticals Inc
  • 72578-062- voriconazole
    • 72578-062-16- 90 TABLET in 1 BOTTLE (72578-062-16)

• 72578- Viona Pharmaceuticals Inc
  • 72578-062- voriconazole
    • 72578-062-77- 10 BLISTER PACK in 1 CARTON (72578-062-77) > 10 TABLET in 1 BLISTER PACK (72578-062-30)

• 72578- Viona Pharmaceuticals Inc
  • 72578-063- voriconazole
    • 72578-063-01- 100 TABLET in 1 BOTTLE (72578-063-01)

• 72578- Viona Pharmaceuticals Inc
  • 72578-063- voriconazole
    • 72578-063-05- 500 TABLET in 1 BOTTLE (72578-063-05)

• 72578- Viona Pharmaceuticals Inc
  • 72578-063- voriconazole
    • 72578-063-06- 30 TABLET in 1 BOTTLE (72578-063-06)

• 72578- Viona Pharmaceuticals Inc
  • 72578-063- voriconazole
    • 72578-063-10- 1000 TABLET in 1 BOTTLE (72578-063-10)

• 72578- Viona Pharmaceuticals Inc
  • 72578-063- voriconazole
    • 72578-063-16- 90 TABLET in 1 BOTTLE (72578-063-16)

• 72578- Viona Pharmaceuticals Inc
  • 72578-063- voriconazole
    • 72578-063-77- 10 BLISTER PACK in 1 CARTON (72578-063-77) > 10 TABLET in 1 BLISTER PACK (72578-063-30)